Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Ranitidine ODT Formulations vs Zantac 150
NCT02195804Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2009
- Primary completion
- Jun 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of ranitidine in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity up to 16 hours and Maximum measured concentration up to 16 hours. Started May 2009; status: completed.
02
Drugs
ranitidine
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02195804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02195804.